The LSD study shows that the 100 mg dose considerably reduces anxiety in the majority of patients

A new study suggests that lysergic acid diethylamide (LSD), also known as acid, could reduce anxiety.

This marks the very first trial to assess the safety and efficiency of MM120 (a pharmaceutical formulation of LSD) in monotherapy for patients with a moderate to severe generalized anxiety disorder, according to the main author Daniel Karlin, MD, MDRMED doctor of Mindmed, a biopharmaceutical company in New York.

The study was published in the Journal of the American Medical Association.

The key to living longer could be linked to a surprising substance, suggests the study

Nearly 200 adults aged 18 to 74 received either a single oral dose from LSD to various DOs, or a “dummy pill”, for a period of three months, according to a press release.

The dosage sessions were organized individually in private rooms with two qualified monitors who observed the participants for at least 12 hours. No psychotherapy has been provided.

A new study suggests that lysergic acid diethylamide (LSD), also known as acid, could reduce anxiety. (istock)

The researchers followed the changes in the anxiety scores of participants in weeks 1, 2, 4, 8 and 12, week 4 being the main evaluation point.

After four weeks, patients receiving the highest doses had significantly lower anxiety scores than the others.

At 12 weeks, 65% of patients taking 100 micrograms showed advantages, with almost 50% in anxiety remission.

Psychedelics as potential mental health treatment are explored by the Trump administration

The researchers also tested the impact of LSD on depression, noting that the highest doses were linked to significant improvements.

Karlin shared that the effects of the LSD were almost immediate. The side effects of the psychedelic included hallucinations, nausea and headache.

LSD has been shown to reduce symptoms in adults with generalized anxiety disorder, with doses of 100 micrograms that prove to be the most effective in a clinical trial. (istock)

The effects were dependent on the dose, 100 micrograms being the optimal dose. THE The 200 micrograms dose also outperformed the placebo. Doses of 25 micrograms and 50 micrograms have not shown significant advantages.

According to Karlin, a possible complication of the study was a “functional denigration”, in which participants in the trial could guess properly if they had received the active drug compared to a placebo, according to Karlin.

A single dose of “magic mushrooms” offers 5 years of relief from depression, researchers find

The drug manufacturer plans to conduct two major trials at an advanced stage to follow patients over a longer period.

If the study is deemed successful, Mindmed will submit the drug to the Food and Drug Administration of the US for approval.

Risks and legality

The LSD is classified as an annex I medication, which means that it is considered a high potential for mistreatment and without accepted medical use, according to the Drug Enforcement Agency.

Annex I drugs are not legally authorized to be prescribed, exempt or used in medical treatment, with the exception of approved research.

If the study is deemed successful, Mindmed will submit the experimental medication to FDA for approval. (istock)

The FDA has appointed LSD, Psilocybin and MDMA as “potential revolutionary therapies,” said Dr. Marc Siegel, Fox News medical analyst, Dr. Marc Siegel.

Miley Cyrus reveals the powerful therapy `Powerful ” who helped her conquer the fear of the scene

“The key is meticulous monitoring and meticulous research, which monitors both side effects and efficiency,” said Siegel.

Click here to obtain the Fox News app

Although this new study shows a “very positive result in around 200 patients”, Siegel has confirmed that the LSD can cause hallucinations.

Additional documented side effects may include paranoia, mood swings, increase in heart rate and long -term psychosis, according to several sources.

“The key is meticulous monitoring and meticulous research, which monitors both side effects and efficiency.”

Hadas Alterman, a lawyer in psychedelic medicine in Washington, DC, told Fox News Digital that “the return of LSD is not only cultural or scientific, it is regulatory”.

The expert says that psychedelics were “sidelined” due to “the radical expansion of the FDA authority as part of the Kefauver – Harris amendments of 1962”.

Click here to register for our Health Newsletter

This legislation, also called the changes in medication efficiency, forced drug manufacturers to provide substantial effective evidence thanks to well -controlled clinical trials before approval.

“The LSD and other psychedelics have long shown a clinical promise, but excessive recreational use in the 1960s avoided researchers to continue to study it,” added Siegel.

“The LSD and other psychedellas have long shown a clinical promise, but excessive recreational use in the 1960s avoided researchers to continue to study it,” said a doctor. (istock)

The secretary of health and social services Robert F. Kennedy Jr. and the secretary of veterans, Doug Collins, aroused interest in exploring psychedelic therapy.

For more health items, visit www.foxnews.com/health

“This line of therapy has a huge advantage if it is given in a clinical environment, and we work very hard to ensure that this happens in the 12 months,” RFK recently told Congress members, by AP.

Psychedelic lawyer Alterman noted that if the support “does not replace science”, he encourages institutions like the FDA to “take this seriously”.